Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Helias, Skopelitis"'
Autor:
A. Karabelis, Petros Kopterides, Christos Kosmas, Nicolaos Mylonakis, Helias Skopelitis, John Syrios, Nicolas Tsavaris, Manolis S. Kallistratos
Publikováno v:
Journal of Cancer Research and Clinical Oncology. 134:75-82
Cardiotoxicity associated with 5-Fluorouracil (5FU) administration has been infrequently reported in literature, albeit various series of acute coronary syndromes have recorded a low but definite incidence of the above toxicity. In the present study,
Autor:
Efstathios Adoniou, Helias Skopelitis, Michalis Zacharakis, Nicolas Tsavaris, Christos Bacoyiannis, George C. Zografos, Nicitas Papadoniou, John Gryniatsos, Efstathios Papalambros, Christos Kosmas, Francheska Sigala, George Papastratis, Evangelos Felekouras, Aristidis Polyzos
Publikováno v:
Chemotherapy. 53:282-291
Purpose: The purpose of the present study was to evaluate the differences in the sequence of administration of 5-fluorouracil (5-FU)/leucovorin (LV) followed by irinotecan (CPT-11), or CPT-11 followed by 5-FU/LV in advanced colorectal cancer (ACC). P
Autor:
Nicolas, Tsavaris, Christos, Kosmas, Helias, Skopelitis, Nicitas, Papadoniou, Aristidis, Polyzos, George, Zografos, Efstathios, Adoniou, John, Gryniatsos, Evangelos, Felekouras, Michalis, Zacharakis, Francheska, Sigala, Christos, Bacoyiannis, George, Papastratis, Efstathios, Papalambros
Publikováno v:
Chemotherapy. 53(4)
The purpose of the present study was to evaluate the differences in the sequence of administration of 5-fluorouracil (5-FU)/leucovorin (LV) followed by irinotecan (CPT-11), or CPT-11 followed by 5-FU/LV in advanced colorectal cancer (ACC).Chemotherap
Autor:
Nicolas, Tsavaris, Christos, Kosmas, Helias, Skopelitis, Panagiotis, Gouveris, Petros, Kopterides, Petros, Kopteridis, Dioynissis, Loukeris, Frantzeska, Sigala, Alexandra, Zorbala-Sypsa, Evangelos, Felekouras, Efstathios, Papalambros
Publikováno v:
Investigational new drugs. 23(4)
Study objectives: The present study was conducted to evaluate the efficacy and safety of the combination of Oxaliplatin, Leucovorin and 5-FU as second line therapy, following relapse to Gemcitabine, in patients with advanced adenocarcinoma of the pan